^
Association details:
| Biomarker: | ALK positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Excerpt:
...- Participants receiving alectinib in either Stage 1 or Stage 2: must be ALK positive as assessed by Food and Drug Administration (FDA) approved test and must...
Trial ID:
Source:
Title:
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
Published date:
06/25/2022
Excerpt:
Adults with treatment-naive, stage IIIB/IV, or recurrent ALK-positive NSCLC were enrolled into a two-stage phase 1b study. Patients received alectinib 600 mg (twice daily during cycle 1 and throughout each 21-d cycle thereafter) plus atezolizumab...Confirmed objective response rate was 86% (18 of 21; 95% confidence interval [CI]: 64-97).
DOI:
10.1016/j.jtocrr.2022.100367
Source:
Title:
Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).
Published date:
06/01/2018
Excerpt:
This phase Ib enrolled treatment-naïve pts with ALK+ aNSCLC regardless of PD-L1 status...At a median follow up of 13 months, (1–22), ORR was 81% (95% CI 58.1–94.6); median progression-free survival was 21.7 months (95% CI 10.3–21.7), median duration of response was 20.3 months (95% CI 11.5–20.3)...
DOI:
10.1200/JCO.2018.36.15_suppl.9009
